Beacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP) produced a successful pivotal trial outcome, setting up an FDA path for the rare vision-loss condition. The company framed the results as demonstrating improved visual acuity versus baseline in a population that has seen limited therapeutic options. The update follows a highly competitive gene-therapy field for inherited retinal disease, where several large-company efforts have struggled to translate early promise into late-stage success. Beacon’s win could sharpen expectations for how gene therapy readouts are designed and interpreted for XLRP. If the trial data hold up in regulatory review, Beacon may become a near-term focal point for investors tracking rare-vision approvals.